Importance is a model-assigned 1–5 on published stories, not a market forecast.
Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.
An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.
Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.
Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.
A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.
Mon · 12 Oct · today
Tue · 13 Oct
Fri · 28 Aug
funding
Boeing filed a current report on Form 8-K under items 1.01, 2.03 and 9.01 - entry into a material definitive agreement and creation of a direct financial obligation, with exhibits. The supplied filing index gives no terms.
Markets open original ↗
product
Evonik is expanding its lipid-based drug-delivery capacity with a new GMP-compliant manufacturing facility in Vancouver. The release states no investment figure or capacity number.
La nouvelle installation conforme aux BPF (bonnes pratiques de fabrication) répondra à la demande croissante en développement de nanoparticules lipidiques (NPL) et en fabrication de produits médicamenteux destinés aux essais cliniques Evonik investit plus de 150 millions CAD (93 millions EUR) Le projet bénéficie d'un financement externe pouvant atteindre 68 millions CAD (42 millions EUR) provenant du Fonds de réponse stratégique du gouvernement fédéral canadien ESSEN, Allemagne , 28 août 2026 /PRNewswire/ -- Evonik investit dans une nouvelle usine de fabrication de médicaments conforme aux BPF…
Markets open original ↗
product
BioNTech shares fell after a setback for its cancer vaccine program, coming days after a win for rival Moderna. No trial figures appear in the supplied text.
Markets open original ↗
product
Novo Nordisk's Wegovy pill has entered the China market, arriving after Eli Lilly's competing oral offering.
Markets open original ↗
product
BioNTech's colorectal cancer vaccine trial failed, and the article reports BioNTech shares fell 8% on the news. The setback lands days after the positive late-stage readout from the rival Moderna/Merck cancer-vaccine program.
Markets open original ↗
